HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $424,593 | -64.7% | 11,115 | -66.7% | 0.00% | -60.0% |
| Q2 2023 | $1,204,017 | +279.8% | 33,380 | +302.2% | 0.01% | +400.0% |
| Q1 2023 | $316,977 | -78.5% | 8,300 | -68.0% | 0.00% | -87.5% |
| Q4 2022 | $1,474,620 | +532.9% | 25,916 | +339.6% | 0.01% | +300.0% |
| Q3 2022 | $233,000 | -61.2% | 5,895 | -60.5% | 0.00% | -66.7% |
| Q4 2021 | $600,000 | -24.5% | 14,912 | -23.7% | 0.01% | -40.0% |
| Q3 2021 | $795,000 | +26.2% | 19,552 | +40.8% | 0.01% | +11.1% |
| Q2 2021 | $630,000 | -4.0% | 13,884 | -11.8% | 0.01% | -18.2% |
| Q1 2021 | $656,000 | +32.8% | 15,743 | +36.0% | 0.01% | +22.2% |
| Q4 2020 | $494,000 | +308.3% | 11,578 | +151.4% | 0.01% | +200.0% |
| Q3 2020 | $121,000 | -1.6% | 4,606 | -31.9% | 0.00% | -40.0% |
| Q3 2018 | $123,000 | +186.0% | 6,765 | +218.4% | 0.01% | +66.7% |
| Q4 2017 | $43,000 | – | 2,125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |